Wedbush Reiterates “Outperform” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Monday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush’s price objective points to a potential upside of 94.86% from the company’s current price.

TLX has been the subject of several other reports. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $11.29 on Monday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $12.48. The stock’s 50 day simple moving average is $11.23 and its two-hundred day simple moving average is $10.16.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently made changes to their positions in TLX. XY Capital Ltd increased its stake in shares of Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. Bank of America Corp DE grew its stake in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Finally, Private Advisor Group LLC boosted its holdings in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.